Online inquiry

IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9383MR)

This product GTTS-WQ9383MR is a type of mRNA modified with Pseudo-UTP, which ecodes the monoclonal antibody that targets IL2R gene. The antibody can be applied in Renal cell carcinoma (RCC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000417.3; NM_000878.5; NM_000206.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3559; 3560; 3561
UniProt ID P01589; P14784; P31785
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9383MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9625MR IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA JNJ-63723283
GTTS-WQ7681MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GEN3013
GTTS-WQ14489MR IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RYI-018
GTTS-WQ5696MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CDX-011 (DOX)
GTTS-WQ7455MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA GBR-830
GTTS-WQ8414MR IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HSP90mab
GTTS-WQ14968MR IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA SHR-1314
GTTS-WQ6869MR IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA DX-2930
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW